Exact Sciences Corp
Open
SectorGezondheidszorg
104.93
Overzicht
Wijziging aandelenprijs
24u
Min
104.9
Max
104.96
Inkomsten | -66M -86M |
|---|---|
Verkoop | 28M 878M |
EPS | -0.21 |
Winstmarge | -9.786 |
Werknemers | 7,100 |
EBITDA | -68M -20M |
Aanbevelingen | Neutraal |
|---|---|
12 Maanden Prognose | +0.09% upside |
Marktkapitalisatie | 404M 20B |
|---|---|
Vorige openingsprijs | 104.93 |
Vorige sluitingsprijs | 104.93 |
Technische score
By Trading Central
Vertrouwen
Strong Bullish Evidence
Exact Sciences Corp Grafiek
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
Gerelateerd nieuws
Peer Vergelijking
Prijswijziging
Exact Sciences Corp Prognose
Koersdoel
By TipRanks
0.09% opwaarts potentieel
12 Maanden Prognose
Gemiddelde 105 USD 0.09%
Hoogste 105 USD
Laagste 105 USD
Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Exact Sciences Corp - Dist. in de afgelopen 3 maanden.
Financieel
$
Over Exact Sciences Corp
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
